Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kathleen McDevitt

Physician Assistant, Medical Oro Valley, AZ Physician Assistant

NPI 1184053035 CMS profile 10520751

2295 E Vistoso Commerce Loop, Oro Valley, AZ 85755

Open in the dashboard

General payments

$9,048

388 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kathleen McDevitt of Oro Valley, AZ is reported in the CMS Open Payments database as having received $9,048 across 388 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,822 82
2024 General $2,978 128
2023 General $1,694 72
2022 General $1,308 57
2021 General $1,247 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kathleen McDevitt
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Kathleen McDevitt were reported at $1,822. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Kathleen McDevitt Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,247 $156 $41–$563 $132
2022 $1,308 $185 $55–$649 $149
2023 $1,694 $199 $58–$717 $160
2024 $2,978 $206 $62–$740 $164
2025 $1,822 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,879 109 payments
  2. Janssen Biotech, Inc. $1,348 69 payments
  3. LEO Pharma Inc. $1,019 29 payments
  4. Genzyme Corporation $783 32 payments
  5. Incyte Corporation $696 12 payments
  6. Regeneron Healthcare Solutions, Inc. $586 25 payments
  7. Pfizer Inc. $422 18 payments
  8. Dermavant Sciences, Inc. $381 16 payments
  9. Lilly USA, LLC $364 18 payments
  10. Novartis Pharmaceuticals Corporation $345 11 payments
  11. Other $1,226 49 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,589 382 payments
  2. Education $460 6 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT $1,374 47 payments
  2. TREMFYA $1,125 48 payments
  3. SKYRIZI $854 47 payments
  4. RINVOQ $746 28 payments
  5. OPZELURA $696 12 payments
  6. ADBRY $681 23 payments
  7. LIBTAYO $410 21 payments
  8. VTAMA $381 16 payments
  9. CIBINQO $328 17 payments
  10. TALTZ $316 16 payments
  11. Other $3,834 214 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

1,090

Median for Physician Assistant: 241

Drug cost

$28,715

Median for Physician Assistant: $4,110

Branded share of claims

3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fluorouracil Generic 138 $8,667
Ketoconazole Generic 185 $4,477
Fluocinonide Generic 87 $3,099
Triamcinolone Acetonide Generic 209 $2,164
Clobetasol Propionate Generic 71 $2,039
Clindamycin Phosphate Generic 43 $1,838
Metronidazole Generic 38 $1,624
Imiquimod Generic 45 $1,349
Doxycycline Hyclate Generic 50 $1,311
Hydrocortisone Generic 119 $730

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$231,196

Of which drugs: $8,501

Medicare patients

1,222

Average age 75

Services billed

6,735

859 women, 363 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 56%
Arthritis 41%
Osteoporosis 20%
Ischemic heart disease 18%
Chronic kidney disease 17%
Cancer 16%
Depression 16%
Diabetes 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 17 22 $6,687

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $639
$639 — —
SKYRIZI
  • AbbVie, Inc. $459
$459 — —
ADBRY
  • LEO Pharma Inc. $357
$357 — —
DUPIXENT
  • GENZYME CORPORATION $147
  • SANOFI-AVENTIS U.S. LLC $95
$242 — —
RINVOQ
  • AbbVie, Inc. $234
$234 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

388 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record